BIO · XBRL financial data

Bio-Rad Laboratories financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	2,546	2,923	2,802	2,671	2,567	2,583
Cost of goods and services sold	1,108	1,282	1,235	1,244	1,188	1,243
Gross profit	1,438	1,641	1,567	1,427	1,379	1,340
Research and development	227	272	257	247	296	276
Selling, general and administrative	800	880	828	842	814	844
Operating income (loss)	411	489	483	338	269	47
Interest expense	22	2	38	49	49	49
Other income (expense)	24	27	45	106	90	90
Income tax expense (benefit)	1,101	1,192	(1,077)	(213)	(498)	236
Net income (loss)	3,806	4,246	(3,628)	(637)	(1,844)	760
Earnings per share, basic USD per share	127.86	142.33	(121.79)	(21.82)	(65.36)	27.87
Earnings per share, diluted USD per share	126.20	140.56	(121.79)	(21.82)	(65.36)	27.85
Weighted average shares, basic millions of shares	30	30	30	29	28	27
Weighted average shares, diluted millions of shares	30	30	30	29	28	27

Fiscal years (BIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	662	471	434	404	488	530
Short-term investments	329	399	1,356	1,203	1,176	1,011
Accounts receivable	419	424	495	489	453	461
Inventory	622	572	719	781	760	741
Total current assets	2,140	1,989	3,158	3,048	3,030	2,906
Property and equipment, net	491	491	499	529	528	540
Right-of-use asset	202	205	181	195	161	170
Goodwill	292	347	406	414	411	580
Total assets	12,973	17,776	13,502	12,299	9,364	10,577
Accounts payable	139	142	135	145	122	129
Total current liabilities	632	681	569	523	468	517
Long-term debt	12	11	1,198	1,199	1,200	1,202
Lease liability, non-current	175	176	154	165	131	146
Total liabilities	3,093	4,109	3,886	3,558	2,795	3,123
Retained earnings	9,268	13,507	9,898	9,261	7,416	8,176
Total stockholders' equity	9,880	13,667	9,615	8,741	6,569	7,454
Total liabilities and equity	12,973	17,776	13,502	12,299	9,364	10,577

Fiscal years (BIO's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	3,806	4,246	(3,628)	(637)	(1,844)	760
Stock-based compensation	42	51	61	61	62	58
Depreciation and amortization	138	134	137	146	152	165
Net cash from operating activities	575	657	194	375	455	532
Purchases of property and equipment	99	121	113	157	166	158
Net cash from investing activities	(60)	(784)	(1,208)	20	(160)	(190)
Proceeds from issuing common stock	7	(2)	(3)	—	—	—
Share repurchases	100	50	216	429	204	296
Repayments of long-term debt	427	3	1	0	0	1
Net cash from financing activities	(523)	(55)	974	(426)	(219)	(283)
Net change in cash	4	(196)	(37)	(30)	85	42

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Bio-Rad Laboratories	465	656	96*	not reported	—	Q3 FY26 10-QSep 30, 2026
Ralliant	366	620	111*	110.9M	—	Q3 FY26 10-QOct 2, 2026
Itron	840	599	102*	43.9M	—	Q3 FY26 10-QSep 30, 2026
Revvity	1,023	730	192*	111.6M	—	Q2 FY26 10-QJul 5, 2026
Vontier	266	757	116*	135.2M	—	Q2 FY26 10-QJul 3, 2026
Bruker	185	839	(77)*	152.4M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Trimble	215	967	150*	229.2M	—	Q3 FY26 10-QOct 2, 2026
Sensata Technologies Holding	553	1,004	225*	145.6M	—	Q3 FY26 10-QSep 30, 2026
Mettler Toledo International	51	1,027	310*	20.0M	—	Q2 FY24 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.